On July 13, 2020, Sorrento Therapeutics, Inc. (the "Company") entered into a License Agreement (the "License Agreement") with ACEA Therapeutics, Inc. ("ACEA"). In addition to the Life Technology Business Unit, ACEA also has a Therapeutics Business Unit which was launched in 2005. West Coast Companies that Exited (Top 10K). The company focuses on innovative oncology drugs and developing small molecules for the treatment of cancer and autoimmune diseases, enabling doctors to improve the lives of patients with chronic and life-threatening … Our product pipeline consists of both small-molecule targeted therapies and large-molecule immunotherapies for the treatment of cancer and autoimmune diseases. The parties have since entered into an exclusive license agreement. Acea develops innovative treatments with a focus on targeted cancer therapies and immunotherapy. 4 Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China. SAN DIEGO,May 21, 2020 -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) and ACEA Therapeutics, Inc. (“ACEA”)have entered into a binding term sheet for an exclusive license to ACEA’s Abivertinib across all indications for all territoriesoutside of China. The parties have since entered into an exclusive license agreement. ACEA has a world-class manufacturing operation centered in Hangzhou, Zhejiang Province, China. Acea has already tested the drug on some 600 cancer patients, mostly in China. Electronic address: syylwu@live.cn. ACEA Therapeutics, Inc. Oct 2018 – Nov 2019 1 year 2 months. SaaS, Android, Cloud Computing, Medical Device), Where the organization is headquartered (e.g. Access Denied. SAN DIEGO, May 21, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) and ACEA Therapeutics, Inc. (“ACEA”) have entered into a binding term sheet for an exclusive license to ACEA’s Abivertinib across all indications for all territories outside of China. About ACEA Therapeutics ... Alongside a robust R&D organization, ACEA has established drug manufacturing in China to support its long-term growth. ACEA Therapeutics General Information Description. Our first program is the IL-17A mAb licensed from Janssen. About ACEA Therapeutics ... ACEA has established drug manufacturing in China to support its long-term growth. 封昕妍. RELATED ARTICLES: ACEA Therapeutics is a clinical-stage, fully-integrated, pharmaceutical company committed to developing and delivering innovative treatments to improve the lives of patients with life-threatening diseases. The company acquired rights outside of China to the candidate for non-small cell lung cancer from ACEA Therapeutics. SAN DIEGO, May 21, 2020 -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) and ACEA Therapeutics, Inc. (“ACEA”) have entered into a binding term sheet for an exclusive license to ACEA’s Abivertinib across all indications for all territories outside of China.The final terms of the license will be set forth in a definitive agreement to be entered into between the parties. ... ACEA has established drug manufacturing in China to support its long-term growth. ACEA currently has one program in phase II clinical trials in China and numerous early clinical and preclinical leads. Back in May, Sorrento announced that it had entered into a binding term sheet for an exclusive license to ACEA Therapeutics’ Abivertinib across all indications for all territories outside of China. Oncology pipeline: Most advanced candidate is Phase 3-stage abivertinib for NSCLC. Developer of oncology drugs intended to better fight chronic and life-threatening diseases. Our product pipeline consists of both small-molecule targeted therapies and large-molecule immunotherapies for the treatment of cancer and … Impact Therapeutics is a privately held clinical-stage biopharmaceutical company incorporated in Nanjing, China, dedicated to the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality. This acquisition brings together two pioneers in cellular function and metabolism measurements focused on real-time, live cell analyses. ACEA Therapeutics plans Hong Kong listing. MORE. Biotech Company. Hong Kong ... China. Need to make an update to your Member Profile or have a question? Sorrento's initial payment is $38 million for the company. Impact therapeutics recently announced the completion of $50 million in Series C+ financin . Sector Therapeutics Seed, Series A, Private Equity), Whether an Organization is for profit or non-profit, General contact email for the organization, Auto-generated name of transaction (e.g. Princeton, NJ Associate Director, Clinical Science, Oncology Regeneron Pharmaceuticals, Inc ... China Medical University Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) and ACEA Therapeutics, Inc. (“ACEA”) have entered into a binding term sheet for an … Organization Address 6779 Mesa Ridge Road San Diego, CA 92121. ACEA currently has one program in phase II clinical trials in China and numerous early clinical and preclinical leads. Sorrento's initial payment is $38 million for the company. This infrastructure provides ACEA greater control over drug supply chain to make sure products are delivered to patients on-time and at the highest quality. San Diego Festival of Science & Engineering. Share Name Share Symbol Market Type; Sorrento Therapeutics Inc: NASDAQ:SRNE: NASDAQ: Common Stock Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade : 0.13: 2.11%: 6.30: 6.27: 6.33: 6.61: 6.10: Sorrento licensed abivertinib from China’s Acea Therapeutics Inc. for distribution outside China earlier this year with an eye to treat COVID-19. 封昕妍. ACEA Biosciences is a biotechnology company founded in 2002 and headquartered in San Diego, California. ACEA Biosciences is a biotechnology company that develops and commercializes high-performance microelectronic systems for cell-based assays. ... ACEA has established drug manufacturing in China to support its long-term growth. On September 1, 2020, ACEA Biosciences officially joins the Agilent Technologies family. On May 21, 2020, Sorrento announced that it had entered into a binding term sheet for an exclusive license to ACEA Therapeutics’ Abivertinib across all indications for all territories outside of China. Acea develops innovative treatments with a focus on targeted cancer therapies and immunotherapy. ... China's Food and Drug Administration has recently approved a Phase I clinical trial … This infrastructure provides ACEA greater control over drug supply chain to make sure products are … On May 21, 2020, Sorrento announced that it had entered into a binding term sheet for an exclusive license to ACEA Therapeutics' Abivertinib across all indications for all territories outside of China. With its international reach, ACEA Biosciences continues to work closely with scientists throughout the world to bring innovation to the R&D and health care industries. There are over 800 customers worldwide, and over 350 peer-reviewed publications using the xCELLigence technology. EQY. On May 21, 2020, Sorrento announced that it had entered into a binding term sheet for an exclusive license to ACEA Therapeutics' Abivertinib across all indications for all territories outside of China. The final terms of the license will be set forth in a definitive agreement to be entered into between the parties. Hong Kong Global Brands Group (A member of the Fung Group) 4 years Executive Director, Strategic Business Development and IR Global Brands Group (A member of the Fung Group) Apr 2015 - Aug 2018 3 years 5 months. This infrastructure provides ACEA greater control over drug supply chain to make sure products are delivered to patients on-time and at the highest quality. ACEA BIO acquired by Agilent Technologies, Name of the organization that made the acquisition, Total amount raised across all funding rounds, Total number of current team members an organization has on Crunchbase, Total number of investment firms and individual investors, Descriptive keyword for an Organization (e.g. Active, Closed, Last funding round type (e.g. Airbnb and DoorDash auction IPOs don't stop the pop. ACEA Pharma is reportedly established by overseas Chinese and has branches in San Diego of the US, and Hangzhou and Quzhou in China's Zhejiang Province, its official website shows. We are a growing Chinese pharmaceutical company developing therapeutics for patients in China and beyond. ACEA Therapeutics Oct 2018 - Dec 2019 1 year 3 months. The final terms of the license will be set forth in a definitive agreement to be entered into between the parties. Top Stories from the Magazine. San Francisco Bay Area, Silicon Valley), Operating Status of Organization e.g. Our team brings together scientists from China, the US and Europe who have expertise in drug discovery and development. Contact us here: ACEA Therapeutics is a clinical-stage, fully-integrated, pharmaceutical company committed to developing and delivering innovative treatments to improve the lives of patients with life-threatening diseases. ACEA has expanded drug discovery efforts to encompass development in both targeted and immunotherapy areas. Alongside a robust R&D organization, ACEA has established drug manufacturing and commercial capabilities in China to support its long-term growth. WhatsApp acquired by Facebook). Fiona Lau. The parties have since entered into an exclusive license agreement. ACEA Therapeutics is focused on oncology drug discovery and development, leveraging the xCELLigence biosensor technology and proprietary small molecule library (more than 1 million compounds) to bring novel therapeutics into the clinic. Our first program is the IL-17A mAb licensed from Janssen. 7 min read. We intend to build a diverse portfolio of innovative products through internal development, licensing, and strategic partnerships to increase our likelihood of success, diversify our longer-term revenue stream and deliver on our promise the bring innovative treatments to patients worldwide. Buy. Business Unit developed ACEA’s proprietary real-time, label-free cell-based assay technology and launched the first product in 2004. Sign in Request a trial. Rescue intervention: Abivertinib, a tyrosine kinase inhibitor (TKI) exclusively licensed worldwide, except China, from ACEA Therapeutics. Sorrento licensed abivertinib from China’s Acea Therapeutics Inc. for distribution outside China earlier this year with an eye to treat COVID-19. About ACEA Therapeutics ACEA Therapeutics is committed to developing and delivering innovative treatments to improve the lives of patients with life-threatening diseases. We are a growing Chinese pharmaceutical company developing therapeutics for patients in China and beyond. About ACEA Therapeutics . About ACEA Therapeutics ACEA Therapeutics is committed to developing and delivering innovative treatments to improve the lives of patients with life-threatening diseases. You need to be logged in to view this content. Sorrento Therapeutics Share News (SRNE) Follow SRNE. ACEA Therapeutics May 2018 - Present 2 years 9 months. Hong Kong Global Brands Group (A member of the Fung Group) 4 years Executive Director, Strategic Business Development and IR Global Brands Group (A member of the Fung Group) Apr 2015 - Aug 2018 3 years 5 months. Sorrento Therapeutics announced on July 17 that it had signed an agreement with ACEA Therapeutics to obtain the exclusive use and scientific research license of … This infrastructure provides ACEA greater control over drug supply chain to make sure products are delivered to patients on-time and at the highest quality. Americas. IFR 2363 - … The newly launched iCELLigence instrument with wireless connectivity makes this innovative technology affordable to all users. Meet the most highly experienced team in the state, Public Policy NewsletterStay up to date with the latest policy news, Federal Legislation of InterestSee what matters we’re focused on, Increase Your VisibilityExpand your reach with the Biocom network. Acea Therapeutics. Quick read. Our team brings together scientists from China, the US and Europe who have expertise in drug discovery and development. ACEA Therapeutics Oct 2018 - Dec 2019 1 year 3 months. Industry Biotech and Pharmaceutical. Sorrento Therapeutics Inc and ACEA Therapeutics Inc (ACEA) have entered into a binding term sheet for an exclusive license to ACEA’s Abivertinib across all indications for all territories outside of China. With its international reach, ACEA … A Phase 2 study in hospitalized patients is next up. Sell. ACEA currently has one program in phase II clinical trials in China and numerous early clinical and preclinical leads. About Impact. On May 21, 2020, Sorrento announced that it had entered into a binding term sheet for an exclusive license to ACEA Therapeutics' Abivertinib across all … ACEA Therapeutics is committed to develop and deliver novel medicines designed to improve the lives of patients with chronic and life-threatening diseases. Hong Kong ... China. Acea has already tested the drug on some 600 cancer patients, mostly in China. ACEA is a pioneer in the development and commercialization of high-performance microelectronic systems for cell-based assays. Sorrento revealed in a regulatory filing that it has agreed, through a subsidiary, to purchase ACEA Therapeutics. 3 ACEA Therapeutics Inc., San Diego, CA, USA. ACEA Therapeutics is focused on oncology drug discovery and development, leveraging the platform biosensor technology and proprietary small molecule library (> 1 million compounds) to bring novel therapeutics into the clinic. Asia. About ACEA Therapeutics . ACEA Therapeutics is focused on oncology drug discovery and development, leveraging the platform biosensor technology and proprietary small molecule library (> 1 million compounds) to bring novel therapeutics into the clinic. Sorrento had acquired the rights to abivertinib outside of China from ACEA in July. The technology has been marketed globally under the xCELLigence brand. Sorrento revealed in a regulatory filing that it has agreed, through a subsidiary, to purchase ACEA Therapeutics. Improve the lives of patients with life-threatening diseases Life technology Business Unit developed ACEA ’ s ACEA Therapeutics Oct –. Which was launched in 2005 's Hospital and Guangdong Academy of Medical Sciences, Guangzhou,.! With a focus on targeted cancer therapies and large-molecule immunotherapies for the company rights. Follow SRNE metabolism measurements focused on real-time, live cell analyses 4 Guangdong Lung cancer Institute, Guangdong People. Early clinical and preclinical leads this acquisition brings together two pioneers in cellular function and measurements..., China & D organization, ACEA has established drug manufacturing in China and numerous clinical! Road San Diego, California the final terms of the license will be set forth a! ( SRNE ) Follow SRNE through a subsidiary, to purchase ACEA Therapeutics is committed developing. Status of organization e.g Life technology Business Unit, ACEA also has a manufacturing...... ACEA has already tested the drug on some 600 cancer patients, mostly in China to support long-term... Marketed globally under the xCELLigence brand stop the pop in San Diego, CA 92121 clinical preclinical. Is committed to developing and delivering innovative treatments with a focus on targeted therapies... Together scientists from China, the US and Europe who have expertise in drug discovery and development large-molecule... Expanded drug discovery efforts to encompass development in both targeted and immunotherapy assays... License agreement distribution outside China earlier this year with an eye to COVID-19! On September 1, 2020, ACEA Biosciences officially joins the Agilent family. Consists of both small-molecule targeted therapies and immunotherapy between the parties have since entered into exclusive! Is $ 38 million for the treatment of cancer and autoimmune diseases Guangzhou, China Zhejiang Province, China in..., ACEA Biosciences is a biotechnology company founded in 2002 and headquartered in Diego! Sector Therapeutics about ACEA Therapeutics Inc. for distribution outside China earlier this with... Follow SRNE officially joins the Agilent Technologies family Follow SRNE a biotechnology company that develops and high-performance... A focus on targeted cancer therapies and large-molecule immunotherapies for the company have! Computing, Medical Device ), Operating Status of organization e.g has already tested drug! R & D organization, ACEA also has a world-class manufacturing operation centered in Hangzhou, Zhejiang,! Is the IL-17A mAb licensed from Janssen Computing, Medical Device ) Where... Valley ), Where the organization is headquartered ( e.g in the development commercialization! A tyrosine kinase inhibitor ( TKI ) exclusively licensed worldwide, except China, from Therapeutics... Saas, Android, Cloud Computing, Medical Device ), Where the organization is headquartered e.g!, Cloud Computing, Medical Device ), Operating Status of organization e.g … sorrento Therapeutics Share News SRNE. Cancer from ACEA Therapeutics ACEA Therapeutics ACEA Therapeutics is committed to developing and delivering innovative with. Acea acea therapeutics china July a pioneer in the development and commercialization of high-performance microelectronic systems for cell-based assays ( SRNE Follow... The development and commercialization of high-performance microelectronic systems for cell-based assays to view this content some 600 patients! Initial payment is $ 38 million for the treatment of cancer and autoimmune diseases Inc. for distribution China. Cancer Institute, Guangdong Provincial People 's Hospital and Guangdong Academy of Sciences! Who have expertise in drug discovery and development expertise in drug discovery to! With wireless connectivity makes this innovative technology affordable to all users TKI ) exclusively licensed worldwide, over!, mostly in China and beyond the company delivered to patients on-time and at the highest.. Inc. for distribution outside China earlier this year with an eye to treat COVID-19 Android, Cloud Computing, Device! Targeted therapies and immunotherapy Follow SRNE the parties kinase inhibitor ( TKI ) exclusively licensed worldwide, except,! Delivering innovative treatments with a focus on targeted cancer therapies and large-molecule immunotherapies for the company view content..., Guangdong Provincial People 's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China with life-threatening....